Shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX – Get Free Report) have been given an average rating of “Buy” by the six ratings firms that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock in the last year is $31.80.
CRGX has been the topic of several recent research reports. William Blair assumed coverage on CARGO Therapeutics in a research report on Tuesday, November 26th. They set an “outperform” rating on the stock. HC Wainwright reissued a “buy” rating and set a $33.00 price objective on shares of CARGO Therapeutics in a report on Friday, November 15th. Finally, Chardan Capital restated a “buy” rating and issued a $28.00 target price on shares of CARGO Therapeutics in a research note on Wednesday, November 13th.
Institutional Inflows and Outflows
CARGO Therapeutics Price Performance
Shares of CARGO Therapeutics stock opened at $13.46 on Friday. The firm has a market cap of $619.56 million, a PE ratio of -3.16 and a beta of 2.50. CARGO Therapeutics has a 1 year low of $10.91 and a 1 year high of $33.92. The stock has a fifty day moving average price of $14.92 and a 200-day moving average price of $17.51.
CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.26. As a group, equities analysts anticipate that CARGO Therapeutics will post -3.73 EPS for the current fiscal year.
About CARGO Therapeutics
CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
Read More
- Five stocks we like better than CARGO Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- MP Materials: Rare Earth Elements Powering the EV Boom
- What is MarketRank™? How to Use it
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- What is a Low P/E Ratio and What Does it Tell Investors?
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for CARGO Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CARGO Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.